Understanding Emgality Side Effects: What Migraine Patients Should Know
Injection site reactions are the most common Emgality side effects, occurring in about 18% of patients
Emgality (galcanezumab) is a CGRP inhibitor medication approved for migraine prevention and cluster headache treatment. Like all medications, Emgality can cause side effects that patients should understand before starting treatment. The most commonly reported side effects in clinical trials include injection site reactions, such as pain, redness, or swelling at the injection site, which occurred in approximately 18% of patients.
Other frequently reported side effects include upper respiratory tract infections, constipation, and allergic reactions. Some patients may experience hypersensitivity reactions, including rash, hives, or difficulty breathing, which require immediate medical attention. Vertigo and fatigue have also been reported in clinical studies, though these occur less frequently than injection site reactions.
Serious side effects are rare but can include severe allergic reactions and cardiovascular events. Patients should discuss their complete medical history with their healthcare provider before starting Emgality, particularly if they have a history of cardiovascular disease or severe allergies. It's important to report any unusual symptoms or side effects to your healthcare provider promptly.
When considering migraine prevention options, patients should work closely with their healthcare providers to evaluate all available treatments, including newer CGRP inhibitors like Qulipta (atogepant), which offers a different mechanism and side effect profile. Each patient's response to migraine medications can vary significantly, making personalized treatment planning essential for optimal outcomes.